WESTMINSTER, Colo.--(BUSINESS WIRE)--Sep. 1, 2009--
Allos Therapeutics, Inc. (NASDAQ:ALTH) today announced the Company will
hold a webcast conference call on Wednesday, September 2, 2009 to
discuss the outcome of the U.S. Food and Drug Administration’s (FDA)
Oncologic Drugs Advisory Committee meeting for FOLOTYN™ (pralatrexate).
FOLOTYN is the Company’s investigational selective antifolate that is
currently being evaluated by the FDA for the treatment of patients with
relapsed or refractory peripheral T-cell lymphoma.
Time: 5:30 pm ET / 4:30 pm CT / 3:30 pm MT / 2:30 pm PT
Date:
September 2, 2009
Dial-in: 877-941-6009 (U.S. and Canada) or
+1-480-629-9771 (international).
Webcast: To access the live audio
webcast or the subsequent archived recording, visit the “Investors -
Presentations and Events” section of the Allos website at www.allos.com.
Webcast and telephone replays of the conference call will be available
approximately two hours after the completion of the call. Callers can
access the replay by dialing 800-406-7325 (domestic) or +1-303-590-3030
(international). The passcode is 4151544#. The webcast will be recorded
and available for replay on the Company's website until September 11,
2009.
About Allos Therapeutics
Allos Therapeutics, Inc. (Nasdaq:ALTH) is a biopharmaceutical company
committed to the development and commercialization of innovative
anti-cancer therapeutics. The Company’s product candidate, FOLOTYN™
(pralatrexate), is a selective antifolate designed to accumulate
preferentially in cancer cells. In May 2009, the FDA accepted the
Company’s NDA for pralatrexate for the treatment of patients with
relapsed or refractory PTCL for priority review and established a
Prescription Drug User Fee Act date of September 24, 2009 for a decision
regarding approval of the NDA. In addition, FOLOTYN is being evaluated
in other tumor types, including solid tumors and a range of lymphoma
sub-types. Allos retains exclusive worldwide rights to FOLOTYN for all
indications. The Company is headquartered in Westminster, CO. For
additional information, please visit www.allos.com.
The Allos logo is a trademark of Allos Therapeutics, Inc.
Source: Allos Therapeutics, Inc.
Allos Therapeutics, Inc.
Monique Greer, 720-540-5268
mgreer@allos.com
